China's 3SBio lays out final $340m go-private proposal
This article was originally published in Scrip
Executive Summary
Following an initial CEO-led proposal last September to take itself private, 3SBio has finalized an agreement that could see the mid-sized Chinese biotech firm delist from Nasdaq in the US in the second quarter of this year.